EXEL | tickerfilter.com

Fundamental analysis

84%

Profitability 86%

Dept financing 50%

Liquidity 54%

Performance 99%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.31%

1 Month

4.12%

3 Months

16.63%

6 Months

33.80%

1 Year

61.99%

2 Year

104.14%

Key data

Stock price

$38.44

P/E Ratio

18.61

DAY RANGE

$37.58 - $38.57

EPS

$1.96

52 WEEK RANGE

$20.14 - $40.02

52 WEEK CHANGE

$63.85

MARKET CAP

9.701 B

YIELD

N/A

SHARES OUTSTANDING

285.252 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-02-2025

BETA

0.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,988,982

AVERAGE 30 VOLUME

$2,460,398

Company detail

CEO: Michael M. Morrissey
Region: US
Website: exelixis.com
Employees: 1,220
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.

EXEL - EXELIXIS, INC.